Reimbursed with a limitationGenericATC L01EA04

Bosutinib Sandoz

Bosutinib Sandoz is a generic from Sandoz Pharmaceuticals AG and is listed on the FOPH Specialities List. Basic health insurance reimburses it within the authorised indication. The public price ranges from CHF 380.70 to CHF 1'733.50 depending on the pack; the co-payment is 10 per cent.

Core data

Authorisation holder
Sandoz Pharmaceuticals AG
ATC code
L01EA04
IT group
07.16.10 Cytostatica
Active substances
Bosutinibum
Preparation type
Generic
On the SL since
01/04/2025
Last price change
01/04/2025
Co-payment
10%

Prices per pack

The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.

Bosutinib Sandoz Price table As of 17/09/2026
Dosage formPack sizeEx-factory pricePublic priceValid fromCat.GTIN
Filmtabl 100 mgBlist 28 StkCHF 334.95CHF 380.7001/04/2025A7680691450013
Filmtabl 400 mgBlist 28 StkCHF 1'339.80CHF 1'473.5501/04/2025A7680691450020
Filmtabl 500 mgBlist 28 StkCHF 1'578.83CHF 1'733.5001/04/2025A7680691450037

Limitation

This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.

The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.

FOPH wordingValid from 01/04/2025

Bosutinib Sandoz ist indiziert für die Behandlung von erwachsenen Patienten mit neu diagnostizierter Philadelphia-Chromosom positiver chronischer myeloischer Leukämie (Ph+ CML) in der chronischen Phase (CP).
Bosutinib Sandoz ist indiziert für die Behandlung von erwachsenen Patienten mit Philadelphia-Chromosom positiver chronisch myeloischer Leukämie (Ph+ CML) in der chronischen Phase, in der akzelerierten Phase sowie in der Blastenkrise, nach Vorbehandlung mit einem oder mehreren c-abl Tyrosinkinase Inhibitoren und wenn eine Behandlung mit Imatinib, Nilotinib oder Dasatinib nicht in Frage kommt.

More preparations in this group

FAQ

Is Bosutinib Sandoz covered by Swiss health insurance?

Yes, but only under conditions. Bosutinib Sandoz is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.

What does Bosutinib Sandoz cost in Switzerland?

The public price is the maximum price set by the FOPH and for Bosutinib Sandoz ranges from CHF 380.70 to CHF 1'733.50 per pack. The ex-factory price ranges from CHF 334.95 to CHF 1'578.83. Pharmacies may not charge more, but may charge less.

Correct or complete this entry

Market access

Do you need your product on the Specialities List?

Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.

  • Independent directory
  • Official FOPH data
  • Website in eight languages
Send an enquiry
Contact

About 2 minutes. No obligation.

First, a little about your business.

Your answers stay in this page until you send your enquiry.

What would you like to achieve?

Your project

Where can we reach you?

You can go back to review your answers before sending.

* Required fields
Prefer email? info@swissreimbursement.com